Viewing Study NCT04204902


Ignite Creation Date: 2025-12-25 @ 4:03 AM
Ignite Modification Date: 2026-01-29 @ 9:09 AM
Study NCT ID: NCT04204902
Status: COMPLETED
Last Update Posted: 2023-11-08
First Post: 2019-12-17
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Healthy View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Tepotinib View
None Bioequivalence View
None Pharmacokinetics View